Total Payments
$11,294
2022 Payments
$22.00
Companies
5
Transactions
9
Medicare Patients
7,181
Medicare Billing
$1.6M
Payment Breakdown by Category
Research$11,093 (98.2%)
Food & Beverage$126.17 (1.1%)
Education$74.67 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,093 | 4 | 98.2% |
| Food and Beverage | $126.17 | 2 | 1.1% |
| Education | $74.67 | 3 | 0.7% |
Payments by Type
Research
$11,093
4 transactions
General
$200.84
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $11,093 | 4 | $0 (2022) |
| Amgen Inc. | $126.17 | 2 | $0 (2018) |
| Astellas Pharma US Inc | $51.00 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $22.00 | 1 | Eli Lilly and Company ($22.00) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $62.75 | 2 | Astellas Pharma US Inc ($51.00) |
| 2019 | $2,234 | 1 | Eli Lilly and Company ($2,234) |
| 2018 | $7,977 | 2 | Eli Lilly and Company ($7,886) |
| 2017 | $986.02 | 2 | Eli Lilly and Company ($951.18) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2022 | Eli Lilly and Company | — | — | In-kind items and services | $22.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/21/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $51.00 | General |
| 08/21/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.75 | General |
| Category: Oncology | ||||||
| 01/08/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,234.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 09/19/2018 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $91.33 | General |
| Category: Oncology | ||||||
| 01/30/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,886.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 11/16/2017 | Amgen Inc. | Neulasta (Biological), NEUPOGEN, Vectibix | Food and Beverage | In-kind items and services | $34.84 | General |
| Category: Oncology | ||||||
| 09/27/2017 | Eli Lilly and Company | — | — | In-kind items and services | $951.18 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $11,071 | 3 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $22.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,755 | 23,979 | $2.5M | $633,231 |
| 2022 | 32 | 1,351 | 11,285 | $1.1M | $258,299 |
| 2021 | 44 | 1,709 | 14,245 | $862,681 | $191,030 |
| 2020 | 52 | 2,366 | 25,882 | $2.0M | $514,783 |
Total Patients
7,181
Total Services
75,391
Medicare Billing
$1.6M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 8,700 | $1.3M | $376,739 | 29.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 6,840 | $559,560 | $162,014 | 29.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 101 | 163 | $111,818 | $16,028 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 159 | $52,510 | $14,861 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 193 | $45,069 | $11,477 | 25.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 228 | 611 | $11,609 | $5,100 | 43.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 201 | 474 | $29,388 | $4,889 | 16.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 202 | 548 | $19,180 | $4,158 | 21.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 17 | 3,120 | $28,080 | $4,119 | 14.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 31 | $14,398 | $4,020 | 27.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 75 | $17,625 | $4,006 | 22.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 53 | $11,501 | $3,249 | 28.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 52 | $15,808 | $2,422 | 15.3% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 21 | 126 | $22,806 | $2,133 | 9.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 66 | 186 | $19,530 | $2,063 | 10.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 42 | $14,028 | $2,045 | 14.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 22 | $6,864 | $2,029 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $9,162 | $1,806 | 19.7% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 48 | $6,768 | $1,187 | 17.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 47 | $7,144 | $990.44 | 13.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 41 | 91 | $8,463 | $969.70 | 11.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 35 | 75 | $4,350 | $965.59 | 22.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 25 | 58 | $4,524 | $954.68 | 21.1% |
| 83550 | Iron binding capacity | Office | 2023 | 35 | 72 | $2,448 | $594.16 | 24.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 19 | 97 | $44,814 | $571.90 | 1.3% |
About Dr. Miho Dougherty, M.D
Dr. Miho Dougherty, M.D is a Internal Medicine healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/21/2009. The National Provider Identifier (NPI) number assigned to this provider is 1184950479.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Miho Dougherty, M.D has received a total of $11,294 in payments from pharmaceutical and medical device companies, with $22.00 received in 2022. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "" ($11,093).
As a Medicare-enrolled provider, Dougherty has provided services to 7,181 Medicare beneficiaries, totaling 75,391 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Eugene, OR
- Active Since 10/21/2009
- Last Updated 07/15/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184950479
Products in Payments
- Kyprolis (Biological) $91.33
- Neulasta (Biological) $34.84
- OPDIVO (Biological) $11.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Eugene
Luke Fletcher, Md, MD
Internal Medicine — Payments: $29,592
Internal Medicine $29,592
Karthik Mahadevan, Md, MD
Internal Medicine — Payments: $6,925
Internal Medicine $6,925
Kirk Jacobson, M.d, M.D
Internal Medicine — Payments: $5,643
Internal Medicine $5,643
Dr. Shehzad Jinnah, Md, MD
Internal Medicine — Payments: $3,561
Internal Medicine $3,561
Dr. Jane Mossberg, M.d, M.D
Internal Medicine — Payments: $2,402
Internal Medicine $2,402
Paul Ehrlich, Do, DO
Internal Medicine — Payments: $1,300
Internal Medicine $1,300